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Bacteria evolve resistance to antibiotics by a multitude of mechanisms. A central, yet 
unsolved question is how resistance evolution affects cell growth at different drug levels. 
Here we develop a fitness model that predicts growth rates of common resistance mutants 
from their effects on cell metabolism. We map metabolic effects of resistance mutations in 
drug-free environments and under drug challenge; the resulting fitness trade-off defines a 
Pareto surface of resistance evolution. We predict evolutionary trajectories of dosage-
dependent growth rates and resistance levels, as well as the prevalent resistance mechanism 
depending on drug and nutrient levels. These predictions are confirmed by empirical growth 
curves and genomic data of E. coli populations. Our results show that resistance evolution, 
by coupling major metabolic pathways, is strongly intertwined with systems biology and 
ecology of microbial populations.  
Modern human and veterinary medicine relies heavily on efficient antibiotics to prevent and cure 
bacterial infections in hospital and community settings. However, due to over- and misuse of 
antibiotics, we are faced with a global increase of antibiotic-resistant bacteria that reduces 
treatment efficacy and increases morbidity and mortality (1). Understanding how and under which 
conditions resistance evolves, and predicting likely trajectories of these dynamics are central goals 
in epidemiology, clinical microbiology, and evolutionary biology (2-6). Furthermore, predictive 
methods for resistance evolution are paramount for public health and drug developers to identify 
the least resistance-prone treatment protocols, drug targets, and new antibiotic candidates (6). 
Several recent advances put such predictions within reach. First, detailed experiments have 
established a number of genotype-fitness maps for antibiotic resistance and have mapped pervasive 
epistasis on these landscapes (7-11). Second, the evolutionary dynamics of resistance and other 
adaptive processes have been studied in parallel laboratory experiments (8, 12-15). These studies 
show that evolutionary change is often broadly distributed and heterogeneous at the genetic level; 
that is, the specific mutations occurring in one population are rarely seen in parallel-evolving 
populations. In contrast, functional targets and phenotypic effects of resistance are more 
repeatable, establishing an important prerequisite for predictability. Insight on the phenotypic basis 
of resistance comes from coupled growth, transcriptomics, and proteomics assays (16-22). These 
studies show that antibiotics cause a global perturbation of the cell’s metabolic network and 
establish models relating core metabolic phenotypes to growth. Third, fitness models, which map 
phenotypic differences to selection, have been established as an important tool for evolutionary 
predictions (4, 5). To predict resistance evolution, we have to compute resistance and growth of 
mutants that establish under a given drug challenge, given input data of drug level and nutrient 
quality. To address this challenge, we develop metabolic fitness models for resistance evolution 
informed by parallel experiments in E. coli under different drug and nutrient levels. These models 
treat drug metabolism and evolutionary response as coupled perturbations of the cell’s metabolic 
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network. They successfully predict evolutionary trajectories of dosage-dependent resistance level 
and growth, including previously unseen resistance mutations.  
Resistance evolution experiments  
This study focuses on resistance evolution in response to the aminoglycoside streptomycin. 
Aminoglycosides act by binding to ribosomes and inhibiting translation. These broad-spectrum 
antibiotics are prescribed against different Gram-negative pathogens and mycobacterial infections 
(23). Streptomycin, in particular, has a well-studied mode of action, and quantitative models of its 
effects on cell metabolism and growth are available (19). Our selection experiments (Luria-
Delbrück assays) elicit resistance mutants in the wild-type E. coli strain MG1655 at different drug 
and nutrient levels (rich medium, glycerol minimal medium). We apply drug concentrations 
moderately above the minimum inhibitory concentration on agar plates (MIC$% = 4	mg/L), 
covering the range 0.9×	– 7.4× half-inhibitory concentration in liquid culture (𝑑/0$% 	= 	8.7	mg/L; 
this concentration reduces growth by 50%). Aminoglycosides require concentrations in this regime 
for clinical response and are typically toxic at higher levels (23). From each plated culture, we 
randomly pick eight different mutants for subsequent detailed analysis. For these mutants, we 
perform whole-genome sequencing and measure the growth rate 𝜆 in liquid culture over the same 
range of drug levels (𝑑 ≤ 	7.4	𝑑/0$%). Growth curves are recorded in units of the wild-type growth 
rate in a drug-free medium, 𝐺 𝑑 = 𝜆 𝑑 /𝜆0$%. 
Resistance mutations identified in this study are found to be broadly distributed over the E. coli 
genome, but they show striking regularities in their functional targets and growth patterns. In rich 
medium and at drug levels up to ~5×𝑑/0$%, most resistance mutations affect membrane-related 
functions associated, in particular, with the electron transport chain. Mutated genes and affected 
metabolic pathways are shown in Fig. S1 and listed in Table S1. Consistent with their common 
functional class, all membrane mutants have growth curves 𝐺 𝑑  with two similarities. First, there 
is a sizeable resistance cost, as measured by the drug-free growth rate relative to the wild type, 𝑊 = 𝜆0/𝜆0$%. Second, drug response is marked by an initially slow decrease of growth followed by 
a rapid decline around the half-inhibitory concentration 𝑑/0	 (Fig. S2, raw data are reported in 
Table S3). Importantly, this common pattern emerges despite considerable genomic variability; 
82% of all membrane mutations are sequenced only in a single clone. Beyond ~5	×𝑑/0$%, mutations 
of ribosome genes become most prevalent; these drug target mutants have amino acid substitutions 
in different residues of the S12 protein encoded by the rpsL gene. 
Drug metabolism and growth  
To explain the observed growth characteristics, we relate the empirical growth curves of 
membrane mutants to drug metabolism (19) (Fig. 1a). Cells maintain an intra-cellular drug level 𝑑9:% by active transport through the cell membrane (with rates 𝛾9: and 𝛾<=%) and growth-induced 
dilution (with rate 𝜆). Intra-cellular drug molecules bind to ribosomes (with an equilibrium 
constant 𝐾), leaving only the unbound fraction of ribosomes, 𝑝@ = 	1 (1	 +	𝑑9:%/𝐾), available 
for translation (18, 19). The resulting growth effect can be described in terms of Monod’s law (16),  𝜆 𝜅G, 𝜅H = 𝐶 𝜅G	𝜅H			𝜅G	 +	 𝜅H	 , (1) 
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Fig. 1. Drug metabolism and resistance evolution. (a) Basic metabolism involves amino acid synthesis 
from extra-cellular nutrients and subsequent synthesis of proteins in ribosomes. These processes take place 
with rates 𝜅G and 𝜅H per unit of proteome, respectively, and result in cell growth with rate 𝜆 (blue arrows). 
Ribosome-targeting drugs (here streptomycin) are transported through the cell membrane (with rates 𝛾9: 
and 𝛾<=%); intra-cellular drug molecules bind to ribosomes (with an equilibrium constant 𝐾) and impact 
growth by reducing 𝜅H (19). Resistance evolution by membrane mutations (cyan) reduces the uptake rates 
of drug and nutrients, 𝛾9: and 𝜅G	.	(b) Monod’s law describes the dependence of the growth rate on 
nutritional and translational capacity, 𝜆(𝜅G, 𝜅H) (shaded surface). Drug effects (reduction of 𝜅H	, orange 
arrows) and resistance evolution by membrane mutations (reduction of 𝜅G, cyan arrows) affect growth in 
mutually dependent ways. Our model establishes computable fitness landscapes for resistance mutants at a 
given drug level (cyan solid line) and in a drug-free medium (cyan dashed line). These landscapes predict 
a maximum-growth trajectory of resistance evolution as a function of drug concentration (light cyan line). 
Rates are shown relative to the wild type in a rich, drug-free medium (dark grey dot; 𝜅H0, 𝜅G$% = 5.9	𝜅H0, 𝜆0$%). 
 
which relates the growth rate to the basic metabolism of the cell (Methods, Fig. 1). Here 𝜅G	is the 
nutritional capacity (the rate of synthesis of biomolecules from external nutrients), and 𝜅H	is the 
translational capacity (the rate of protein synthesis per ribosome); both rates are measured per unit 
of proteome. The pre-factor 𝐶 = 𝜆LMN/𝜅H is related to the maximum attainable growth rate.	A 
ribosome-targeting drug impairs growth by reducing translation; that is, the growth rate follows 
Monod’s law with constant 𝜅G		and drug-dependent 𝜅H	 𝑑 = 	𝑝@ 𝑑 	𝜅H0, where 𝜅H0 is the drug-free 
translational capacity (Fig. 1b). Specifically, the model of Greulich et al. (19) establishes 
computable drug response curves depending on two effective parameters: the rate scale 𝜆∗ =	2(𝛾<=%	𝜅H0𝐾)Q/R, which determines the shape of the growth curve, and the concentration scale 𝑑∗ =𝜆LMN𝜆∗/(2𝜅H0𝛾9:), which sets characteristic drug levels for growth inhibition.  By fitting this model 
to growth data of membrane mutants, we obtain growth curves 𝐺(𝑑) that depend on the drug 
response parameters 𝑑∗, 𝜆∗ and one model-independent fit parameter, the drug-free growth rate 𝑊 
(Methods). Remarkably, the maximum-likelihood fits reproduce the growth data within 
experimental errors, validating the underlying metabolic model (19) for our membrane mutants 
(Fig. S2). For each mutant, the inferred parameters 𝑑∗, 𝜆∗ yield estimates of the relative membrane 
transport rates, 𝛾9:/𝛾9:$% and 𝛾<=%/𝛾<=%$% , and the fitted growth curve provides the empirical 
resistance level 𝑅 = 	𝑑/0/𝑑/0$% (Table S2).  
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Fitness model of drug resistance  
The mutant growth data reveals a simple, universal mechanism of membrane-based resistance 
evolution. This mechanism relates two a priori independent phenotypes: the resistance level, 𝑅, 
and the drug-free growth rate, 𝑊. We find both quantities to depend in a monotonic way on the 
relative drug uptake rate, 𝜀 = 	𝛾9:/𝛾9:$%; this pattern is common to all membrane mutants except 
one outlier (Fig. 2ab). Moreover, the drug-free growth 𝑊(𝜀) follows Monod’s law at constant 𝜅H 
(Fig. 2b, cf. Fig. 1b); hence, the parameter 𝜀 also equals the relative nutritional capacity,  𝜀 = 	 𝛾9:𝛾9:$% 	= 	 𝜅G𝜅G$% 	 . (2) 
Together, membrane resistance mutations generate a proportional reduction of drug and nutrient 
uptake depending on a single permeability parameter 𝜀. This coupled effect is consistent with the 
underlying molecular transport processes; nutrients present in rich growth media and 
aminoglycosides both require active uptake mechanisms involving proton motive force (23). 
Combined with the model of drug metabolism (19), equation (2) specifies the growth rate or 
absolute fitness, 𝐺(𝑑, 𝜀), of mutants with permeability 𝜀 at drug level 𝑑	(Methods). This fitness 
model predicts the drug-free growth rate and resistance level for mutants of effect 𝜀,  𝑊 𝜀 =	 𝜀	(𝑞$% + 1)(𝜀𝑞$% + 1) ,														𝑅 𝜀 = 𝑟$%	𝑊 𝜀 + 1 (𝑟$%	𝑊 𝜀 )𝜀(𝑟$%	 + 1 𝑟$%	) , (3) 
depending on the wild type parameters 𝑞$%	 = 𝜅G$%/𝜅H$% and 𝑟$%	 = 𝜆0$%/𝜆∗$% (Fig. 2ab). With 
values 𝑞$% = 	5.9	(5.5, 6.3), 	𝑟$% = 	5.4	(5.3, 5.6) inferred from growth data, the relations (3) 
generate a unique evolutionary tradeoff 𝑊(𝑅), which relates the resistance effect of membrane 
mutations and the collateral cost in drug-free growth (Fig. 2c). Without further fit parameters, the 
model predictions are in quantitative agreement with the empirical data reported in Fig. 2. 
Importantly, the tradeoff 𝑊(𝑅) depends on the underlying evolutionary mechanism of equation 
(2) and on broad metabolic characteristics of the wild type; however, it does not involve genetic 
details of specific resistance mutations. In particular, the initial slope 𝑊Y 𝑅 = 1 =−(𝑞$%	 + 2/(1 + (𝑟$%	)R)[Q, predicts a universal weak-effect tradeoff: starting from our 
susceptible wild-type E. coli strain, 10% resistance increase costs 2% in drug-free growth.  
To further characterize membrane-based resistance evolution, we assess the effects of drug release 
by outward transport. The inferred variation in 𝛾<=% across our set of mutants turns out to have 
negligible effects on growth (Fig. S3), as confirmed by model variants that include evolution of 𝛾<=% (Fig. S5). This weak dependence reflects the metabolic regime relevant for our experiments, 
where intra-cellular drug levels are depleted predominantly by growth and not by outward 
transport (19). It is also consistent with the observed molecular targets of membrane mutations. 
These affect membrane functions associated with electron transport but do not overlap with known 
efflux pathways (Fig. S1).  
 
Predicting trajectories of resistance evolution 
Next, we use the fitness model to predict resistance evolution in response to a given drug challenge. 
At a given drug level 𝑑, the growth rates 𝐺(𝑑, 𝜀) define a fitness landscape for membrane mutants 
of different permeability (i.e. uptake rate) (Fig. 1b). There is a specific drug level 𝑑\ 𝜀 	where 
mutants of permeability 𝜀 have maximum fitness (i.e., relative growth rate) compared to all other 
 
	 5	
 
 
 
Fig. 2. Resistance evolution by membrane mutations. (a, b) Resistance, 𝑅	 = 𝑑/0/𝑑/0$%, and drug-free 
growth, 𝑊	 = 𝜆0/𝜆0$%, are plotted against the evolutionary change in membrane uptake rates, 𝜀	 = 𝛾9:/𝛾9:$% 
= 𝜅G/𝜅G$%; see equation (2). (c) Evolutionary resistance-cost trade-off, obtained by plotting 𝑊	against 𝑅. 
Data points are obtained from experimental growth curves of membrane mutants (Methods, Table S2); bars 
give rms. measurement errors. Mutants are elicited in Luria-Delbrück assays at drug levels 𝑑]^/𝑑/0$% = 0.9, 1.8, 3.7 (violet, pink, red); the wild type is shown for reference (gray).  Model predictions (dashed cyan 
lines) are given by equation (3); the predicted drug-free growth rate 𝑊(𝜅G/𝜅G$%) follows Monod’s law at 
constant 𝜅H (cf. Fig. 1b). Growth condition: rich LB, 𝜆0$% = 	2.0/hr, 𝑑/0$% = 8.7mg/L.	Model parameters: 𝑞$% = 	5.9, 	𝑟$% = 	5.4. 
 
 
 
 
Fig. 3. Predicting mutant growth and resistance. (a) The predicted maximum-growth trajectory, 𝐺\(𝑑) 
(light cyan line, cf. Fig. 1b) with onset point for resistance evolution (diamond) is compared to data of 
membrane mutants in liquid culture. For each mutant, empirical 𝐺 and 𝑅 values are shown at the predicted 
maximum-fitness point (dots, colors as in Fig. 2, bars give rms. experimental errors). Almost all other 
growth measureents (gray points) are below the predicted maximum-growth trajectory. (b) The predicted 
resistance of maximum-growth mutants, 𝑅\(𝑑), is compared to empirical 𝑅 values shown at the predicted 
maximum-fitness point. Growth conditions: as in Fig. 2. 
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membrane mutants. We can express this growth rate,  𝐺\ 𝜀 = 	 𝜀	(𝑞$% + 1)𝜀𝑞$% + 2 , (4) 
and the corresponding drug level 𝑑\ 𝜀 , in terms of the wild type parameters 𝑞$%, 𝑟$% (Methods). 
Plotting 𝐺\ 𝜀  vs. 𝑑\ 𝜀  produces a key model prediction: the maximum growth trajectory of 
membrane resistance mutants at a given drug challenge, 𝐺\ 𝑑  (Fig. 3a, see also Fig. 1b). 
Geometrically, this trajectory is obtained as the envelope of the underlying family of growth 
curves. Together with equation (3), we can also compute the resistance of maximum-fitness 
mutants, 𝑅\ 𝑑  (Fig. 3b). To test these predictions, we plot the empirical growth rate of each 
membrane mutant at its predicted maximum-fitness drug level, 𝐺(𝑑\)	(Fig. 3a), and we plot the 
empirical resistance 𝑅	against 𝑑\ (Fig. 3b). Both empirical patterns are in quantitative agreement 
with model predictions.  
When will these maximum-fitness mutants be seen in selection and evolution experiments? To 
address this question, we evaluate the rate of resistance evolution in Luria-Delbrück assays (Fig. 
4a). At moderate drug levels, we find resistance origination rates 𝑈c 𝑑 = 10[d − 10[e, from 
which we infer membrane mutation rates that decrease with increasing effect 𝑅	(Methods, Fig. 
S5). Together with our fitness model, this mutational spectrum predicts the range of growth rates 
likely to be observed in Luria-Delbrück selection experiments (shown as gray squares in Fig. 4b). 
These rates cluster into a narrow corridor below the maximum growth rate 𝐺\ 𝑑 , which is 
constrained by two effects: mutations of larger resistance effects rapidly become rare, whereas 
mutations of smaller effects have rapidly decreasing growth rates (Fig. S5). Observed growth rates 
consistently cluster into this corridor; a similar clustering around 𝑅\ 𝑑 	is observed for resistance 
effects (Fig. S5). Under subsequent short-term evolution at the same drug level, clonal interference 
between resistant clones is expected to further prune growth and resistance spectra towards the 
optimal values 𝐺\ 𝑑  and 𝑅\ 𝑑 .	 
 
Evolutionary switches between resistance mechanisms  
Beyond growth and resistance predictions for a given mechanism, evolutionary models can also 
predict the prevalent resistance mechanism itself. First, the wild type increases its ribosome content 
in response to ribosome-targeting drugs (17, 19), 𝜌$% 𝑑 	~	𝜅G$%/(𝜅H$%(𝑑) +	𝜅G$%), which can be 
regarded as a resistance mechanism based on regulation. This mechanism confers a substantial 
growth benefit at low drug levels, as can be seen by comparing the wild type growth curve with 
its counterpart in a hypothetical cell with a constant, unregulated ribosome content (Fig. 4a). 
Resistance by regulation is the dominant mechanism at low drug levels, because any evolutionary 
change with a cost in a drug-free environment (𝑊 < 1) can only be under positive selection 
beyond a minimum drug level (3).  
Our membrane resistance model predicts an evolutionary switch from regulation to membrane 
evolution with an onset point 𝑑iL 𝑞$%, 𝑟$% = 	𝑑\ 𝜀 = 1 	(Fig. 4b). At our wild type parameters, 
the predicted onset point 𝑑iL/𝑑/0$% ~ 1/2 is consistent with the experimentally observed onset of 
membrane-based resistance evolution below the wild-type MIC (9). At higher drug levels, 𝑑/𝑑/0$% > 5, membrane mutations have low mutation rates (𝑈c 𝑑 < 10[Q0, Fig. S5) and low 
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Fig. 4. Predicting mechanisms of drug resistance. (a, c) Rates and phenotypes of resistance mutations in 
rich agar and minimal glycerol at different drug levels (cyan: membrane mutations; orange: rpsL, ribosome 
target mutations; green: cpxA, stress response). (b, d) Prevalent growth rates and resistance mechanisms 
depend on drug and nutrient levels. Observed growth rates (measured in liquid culture) of Luria-Delbrück 
mutant colonies are shown together with the predicted corridor of likely growth rates (gray squares show 
growth rate intervals with probability ≥ 0.04, see also Fig. S5). Model predictions of maximum-growth 
trajectories for different resistance mechanisms: regulation of ribosome content in the wild-type (gray line) 
compared to hypothetical cell with constant ribosome content (dotted gray line), membrane permeability 
reduction (light cyan line) with onset point 𝑑iL in rich medium (diamond), cpR stress response system 
(green line, fitted growth curve, see Fig. S2). The growth rate ranking of mechanisms is emphasized by 
color shading. Horizontal lines mark a low-growth regime where different metabolic regimes are expected. 
Growth conditions and model parameters: rich medium (𝜆0$% = 	2.0/hr, 𝑑/0$% = 8.7mg/L used as unit for 
all drug levels,	𝑞$% = 	5.9, 	𝑟$% = 	5.4), glycerol minimal medium (𝜆0$% = 	0.39/hr, 𝑞$% = 0.2, 	𝑟$% =1.03). 
 
 
 
model-based growth rates 𝐺\ 𝑑  (below the detection threshold in a Luria-Delbrück assay for 𝑑/𝑑/0$% > 10), predicting another switch to a viable resistance mechanism. That switch is observed: 
in the regime 𝑑/𝑑/0$% = 5 − 12,	most resistant clones have mutations in the rpsL gene, which 
encodes the ribosomal protein S12 (Fig. 4a). These target mutations confer high resistance with a 
flat maximum growth rate 𝐺H = 0.95 in this drug regime, albeit at low mutation rate, 𝑈H ∼ 10[Q0.  
Our model predicts a similar grading between resistance mechanisms in short-term evolution (Fig. 
S5). At intermediate drug levels and population sizes (𝑁 ≳ 𝑈c[Q 𝑑 	~10d − 10e), resistant clones 
are expected to harbor membrane mutations but no target mutations, implying growth rates of 
order 𝐺\ 𝑑  as discussed above. This regime is relevant for infections; for example, typical urinary 
tract and blood infections involve populations of size 𝑁 < 10e (24, 25). In very large populations 
(𝑁 ≳ 𝑈H[Q), membrane mutations will be outcompeted by target mutations with growth rate 𝐺H.	Importantly, metabolic fitness models predict the optimal resistance mechanism to depend not 
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only on the drug level, but also on nutrient conditions. Specifically, membrane mutations reduce 𝜅G by affecting nutrient intake, which is an affordable resistance mechanism in rich media but 
becomes costly in poor media. Conversely, ribosome target mutations reducing 𝜅H have higher 
metabolic costs in rich media (Fig. 1b), in accordance with previous results (26). This predicts a 
shift in prevalence towards target mutations with decreasing nutrient quality. To test this 
prediction, we select resistance mutants by Luria-Delbrück assays in a M9-minimal glycerol 
medium, which has a 5-fold reduced wild-type growth rate compared to rich medium (Fig. 4cd). 
The resulting model-based maximum growth rates 𝐺\ 𝑑  of membrane permeability mutations are 
below the detection threshold for all drug levels. Consistently, these mutations are never observed 
despite their substantial mutation rate, and target mutations become the prevalent resistance 
mechanism already at intermediate drug levels. At low drug levels, target mutations are superseded 
by a new class of low-cost, intermediate-rate (𝑈\op~10[q) resistance mutations in the gene cpxA. 
These mutations activate the Cpx stress response system (27), which confers resistance to 
aminoglycosides (28) and affects nutrient intake by regulating porins (29). Because drug and 
nutrients are affected via different pathways, this resistance mechanism can lead to higher growth 
rates than a proportional-reduction mechanism constrained by equation (2).  
More broadly, metabolic fitness models can serve to rank different resistance mechanisms. For 
example, overexpression of efflux pumps is a ubiquitous resistance mechanism observed in 
response to many antibiotics, including aminoglycosides, fluoroquinolones, tetracyclines and 𝛽-
lactams (30, 31). Here we use a minimal fitness model with coupled effects on efflux rates and on 
proteome allocation to estimate maximum-growth trajectories for this mechanism (Fig. S4). For 
the growth conditions of our system, these trajectories remain below those of membrane-based 
resistance throughout the intermediate drug regime. The predicted inefficiency of efflux pumps is 
a consequence of the underlying metabolic regime, where intracellular drug is depleted 
predominantly by growth (19). It is consistent with the absence of efflux mutants in our Luria-
Delbrück selection experiments. Notably, shape and parameter dependence of growth trajectories 
differ considerably between mechanisms, which opens the perspective of using empirical growth 
curves together with metabolic modeling to infer properties of unknown resistance pathways.  
Conclusion  
We have established an evolutionary model of drug resistance that predicts tradeoff functions 𝑊 𝑅  and maximum-growth trajectories 𝐺\ 𝑑  for families of mutants carrying specific resistance 
mechanisms. Tradeoff functions can be regarded as Pareto fronts constraining the simultaneous 
optimization of drug resistance and growth in a drug-free medium (32, 33). Maximum growth 
trajectories determine optimal resistance levels for a given mechanism and predict evolutionary 
switches between mechanisms as a function of drug and nutrient conditions. Such Pareto fronts 
and maximum-growth trajectories apply to short-term evolution by common resistance mutants.  
This regime is critical for the immediate survival of a microbial population under a drug challenge 
and relevant in clinical contexts. However, rare mutants operating on different mechanisms can 
reach over the Pareto front, and over longer evolutionary times, compensatory mutations are 
expected to mitigate resistance costs. Thus, including multiple mutations and compensatory traits 
into metabolic fitness models of resistance is an important avenue for future research (9, 11).  
Predictive analysis of resistance evolution can help drug and therapy design by identifying likely 
resistance pathways for detailed experimental scrutiny. Our method is applicable to a wide range 
of antibiotics and resistance mechanisms, depending on two key prerequisites of predictability. 
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First, the dominant resistance trait has a sufficient mutational supply covering a spectrum of 
resistance effects, so that high-fitness resistance mutants are continuously present in a typical 
population. This condition is fulfilled in our experiments, as well as for a number of clinically 
relevant antibiotics, including fluoroquinolones and aminoglycosides. Predictability of resistance 
levels and growth rates is then generated by functional convergence towards an efficient resistance 
mechanism and tuning of this mechanism on its Pareto front (Fig. 3 and 4). Thus, predictability 
extends to previously unseen mutations, in tune with the broad genomic distribution of adaptive 
mutations observed here and in other studies (5, 14). Second, we have a quantitative biophysical 
model for drug action and resistance mechanisms. The arguably best-understood case of ribosome-
targeting drugs (18, 19) is the focus of this paper; similar models appear within reach for other 
drugs targeting core metabolic pathways, such as the fluoroquinolone ciprofloxacin (34), as well 
as for drug combinations (35).  
Our results highlight that drug action and resistance evolution are global, mutually dependent 
perturbations of a microbial system (Fig. 1b). Both act on the cell’s metabolic network, but often 
on different components. The central role of cell metabolism for resistance evolution explains a 
key finding of this paper: optimal resistance effects and mechanisms strongly depend on the 
ecology of the microbial population, in particular, on its nutrient supply. Accounting for such 
environmental effects is crucial for translating laboratory experiments on resistance into clinical 
applications.  
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 Methods  
 
1. Experimental procedures  
 
Bacterial strains, growth media. The bacterial strain used in these experiments was Escherichia 
coli K-12 MG1655. The streptomycin-resistant clones derived from this ancestral strain are listed 
in Table S3. Experiments in rich nutrient medium were performed in LB (liquid medium) and LB 
agar (solid medium, Sigma-Aldrich), and experiments in poor nutrient medium were performed in 
0.2% glycerol M9-minimal medium (36). All experiments were performed at 37 °C.  Minimum 
inhibitory concentrations (MIC) under different nutrient conditions were determined by plating a 
10−7 dilution of an overnight-grown culture at different concentrations of streptomycin. For the 
wild-type strain, we measured a streptomycin MIC of 4 mg/L in rich agar and 2 mg/L in M9-
minimal glycerol agar.  
Mutation rate data and isolation of mutants. We determined the mutation rate of resistance at 
different streptomycin concentrations from classical Luria-Delbrück fluctuation assays. At 
intermediate drug concentrations used for selection in LB agar (𝑑 = 8, 16, 32, 64 mg/L), we started 
40 independent cultures of 103 cells from an overnight culture. From the number of colonies and 
the mean number of plated cells across these 40 parallel cultures, we computed drug-dependent 
mutation rates, using the bz-calculator for mutation rates (37). Colonies obtained from these tests 
were re-streaked on plates with the same streptomycin concentration. To determine the mutation 
rates of rpsL variants, we plated 20 – 50 independent overnight cultures of 103 initial cells at higher 
drug levels (𝑑 =	48, 64, 100, 128 mg/L). In minimal glycerol medium, we used 10 – 20 
independent cultures at 𝑑 = 8, 16, 32 mg/L. Mutation rates and frequencies of different variants 
are given in Table S5. 
Growth rate measurements. Measurements in the exponential growth phase were performed 
with a Bioscreen plate reader	at	OD600, with measurements taken every 4 minutes. To calculate 
the maximum exponential growth rate from the OD600 data, we used KaleidaGraph for optical 
density (OD) values between 0.02 to 0.09. Overnight-grown cultures of three biological replicates 
in rich LB medium or glycerol minimal medium were diluted 1:1000 and were then used for 
growth rate measurements. The (exponential) growth rate of the wild-type strain in a drug-free 
medium serves as a reference to scale all growth rates measured in this study. Raw data is reported 
in Tables S3 (rich LB medium) and S4 (M9-glycerol minimal medium). 
Whole genome sequencing and sequence analysis of resistant clones. We performed whole-
genome sequencing to identify the genetic basis of resistance phenotypes at different streptomycin 
concentrations. DNA extraction was performed on 1 mL of overnight-grown cultures by using the 
Epicentre DNA extraction kit and following the manufacturer’s protocol. We used Illumina’s 
Nextera XT kit to make genomic libraries (2 x 300) that were subsequently sequenced on the 
Illumina platform. Miseq. Samples were dual-indexed and pooled together, resulting in an average 
whole-genome coverage of 30X per sample. We used CLC genomics Workbench version 8 for the 
analysis of the fastq files obtained from Miseq sequencing to identify point mutations and small 
indels. To identify large deletions or transposon movements, we ran the fastq files through Breseq 
(version 0.27.1a) (38).  
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2. Fitness models for drug resistance  
 
Cell metabolism and growth. Monod’s law, as given in equation (1), relates the rate of 
exponential growth with the underlying core metabolism of the cell. To derive this relation, we 
assume there are two rate-limiting processes: the conversion of external nutrients into amino acids 
and the subsequent synthesis of proteins by ribosomes. These processes define a distribution of 
cellular resources: a fraction 𝜑G of the proteome is allocated to amino acid synthesis and a fraction 𝜑H = 1 −	𝜑G to protein synthesis. Given process rates 𝜅G and 𝜅H, the resulting growth rate in the 
exponential regime takes the form  𝜆 𝜅G, 𝜅H = max (𝛥𝜑G)	𝜅G, (𝛥𝜑H)	𝜅H (5) 
with 𝛥𝜑G = 	𝜑G − 𝜑G,0 and 𝛥𝜑H = 	𝜑H − 𝜑H,0, where 𝜑G,0 and 𝜑H,0 are baseline values of 
proteome fractions unrelated to growth. Inserting the constraint 𝜑G +	𝜑H = 1	shows that the 
maximum is attained if the flux balance condition 𝛥𝜑G 	𝜅G = 	 𝛥𝜑H 	𝜅H (6) 
is fulfilled, in accordance with experimental observations (17, 39, 40). This condition requires a 
regulated ribosome content,  𝛥𝜑H = 𝐶 𝜅G𝜅G + 𝜅H , (7) 
where 𝐶 = 1 − 𝜑G,0 − 𝜑H,0 = 𝛥𝜑H,LMN = 𝜆LMN/𝜅H is the maximum proteome fraction of 
ribosomes contributing to growth. Inserting equation (7) into equation (5), we obtain Monod’s law, 
equation (1). The Monod growth rate 𝜆(𝜅G, 𝜅H) is plotted in Fig. 1b.  
Metabolism of ribosome-targeting drugs. Here we summarize the metabolic model for 
ribosome-targeting drugs developed by Greulich et al. (19, 41) which is the basis of our metabolic 
fitness models. The action of the drug takes place in three steps (Fig. 1a). Given an extracellular 
drug level 𝑑, membrane transport of unbound drug molecules (with rates 𝛾9: and 𝛾<=%) and dilution 
by growth (with rate 𝜆). Intra-cellular drug molecules bind to ribosomes (with an equilibrium 
constant 𝐾). These dynamics generate a steady-state intra-cellular drug concentration 𝑑9:%, 
impairing a fraction 1 − 𝑝@ = 	1 (1	 +	𝐾/𝑑9:%) of the ribosomes. The action of the drug results 
in a growth reduction  𝜆𝜆0 = 𝑔 𝑑𝑑∗ , 𝜆0	𝜆∗	 , (8) 
depending on the drug response parameters  𝜆∗ = 	2 𝛾<=%	𝜅H0𝐾,													𝑑∗ = 	𝐶	𝜆∗2𝛾9: , (9) 
where the metabolic constants 𝜅H0 and 𝐶	=	𝜆LMN/𝜅H0 refer to drug-free growth. Introducing the 
scaled variables 𝛿 = 𝑑/𝑑∗	and 	𝑟 = 𝜆0/𝜆∗, the drug response curve 𝑔(𝛿, 𝑟) can most easily be 
written in terms its inverse function, 𝛿 𝑔, 𝑟 = 	 12𝑟𝑔 1	– 	𝑔	 + 	4		𝑟R𝑔R	– 	4		𝑟R𝑔{ , (10)	 
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which specifies the scaled drug level 𝛿 required for a growth reduction 𝑔. In particular, the half-
inhibitory concentration is given by  𝑑/0𝑑∗ = 	12	 𝑟 + 1𝑟 . (11) 
This model shows that drug action is a perturbation of the cell’s core metabolism that is shaped by 
two important nonlinearities. First, the dilution of intra-cellular drug levels by cell divisions 
introduces a negative feedback between drug level and growth, which can generate fitness cliffs 
with a sudden drop in growth at a threshold drug level (18, 19, 42). Second, under a drug-induced 
reduction of the translational capacity, 𝜅H	 𝑑 = 	𝑝@	𝜅H0, cells upregulate their ribosome content 
according to equation (7), mitigating the drug effect on growth. From equations (1) and (7), the 
drug-dependent proteome fraction of ribosomes can be written in the form  𝛥𝜑H(𝑑, 𝑞) = 𝐶 𝑞 + 1 − 𝑔𝑞 + 1 	, (12) 
where 𝑞 = 	𝜅G/	𝜅H is the ratio of metabolic rates in a drug-free environment and 𝑔 is given by 
equation (10). To display the contribution of ribosome regulation to drug defense, we evaluate 
growth curves of a hypothetical cell with its ribosome content constrained to the drug-free value, 𝛥𝜑H 	= 𝐶𝑞/(1 + 𝑞). Constrained cells violate the flux balance condition (6) in the presence of the 
drug. To introduce the constraint into the metabolic model of drug action, we self-consistently 
determine a metabolic ratio 𝑞, such that 𝛥𝜑H(𝑑, 𝑞) =	𝐶𝑞/(1 + 𝑞). A straightforward calculation 
then determines the growth curve 𝑔=i 𝛿, 𝑞, 𝑟 	of the constrained cell, which can again be written 
in terms its inverse function, 𝛿=i 𝑔, 𝑞, 𝑟 = 	𝛿 𝑔𝑞 + 1𝑞 + 1 , 𝑔 𝑞 + 1𝑔𝑞 + 1 𝑟 (13) 
with 𝛿 . , .  given by equation (10). Fig. 4a shows the growth curve 𝑔=i 𝑑/𝑑∗, 	𝑞$%, 	𝑟$%  for our 
wild type. Ribosome regulation is seen to partially compensate the drug effect on growth in the 
sub-lethal dosage regime. In particular, 𝑑/0$% is significantly higher than for the constrained cell.  
Fitness model for drug resistance evolution. We assume that a given mechanism of drug 
resistance generates a quantitative molecular resistance trait and a family of mutants with different 
trait amplitude 𝜀. We also assume that the resistance mutants follow the same metabolic model of 
drug action as the wild type and have computable changes in core metabolism (with parameters 𝜅G, 𝜅H, and 𝐶) and drug interactions (with parameters 𝛾9:, 𝛾<=%, and 𝐾). This input determines a 
fitness model specifying the growth of mutants with a given resistance amplitude at a given drug 
level, 𝜆/𝜆0$% = 	𝐺(𝜀, 𝑑/𝑑∗$%; 	𝑞$%, 𝑟$%). The fitness model takes the general form  𝐺 𝜀, 𝑑 = 	𝑊 𝜀 	𝑔 1𝐷 𝜀 𝑑𝑑∗$% ,𝑊 𝜀𝐿 𝜀 	𝑟$% 																																			(14) 
with transformation functions  𝑊 𝜀 =	𝜆0 𝜀𝜆0$% 	,																			𝐷 𝜀 = 	𝑑∗ 𝜀𝑑∗$% 	,																			𝐿 𝜀 = 	 𝜆∗ 𝜀𝜆∗$% (15) 
quantifying the effects of the resistance trait on drug-free growth and on drug response. Here we 
have temporarily suppressed the dependence of the functions 𝐺,𝑊,𝐷, 𝐿 on the wild type 
parameters 𝑞$%, 𝑟$%. For a given resistance mechanism, the fitness model of equations (14) and 
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(15) establishes a computable relation between evolutionary changes, drug and nutrient conditions, 
and growth. Specific forms of this model for the different resistance mechanisms discussed in this 
paper will be given below.  
Resistance trade-off function. For a given resistance mechanism, the fitness model of equations 
(13) and (14) predicts a unique relation between the level of resistance, 𝑅 = 𝑑/0 𝑑/0$%, and the 
corresponding cost in a drug-free medium, 𝑊 = 𝜆0 𝜆0$%. This tradeoff can be computed in 
parametric form, using the relations 																𝑊 𝜀 ,																					𝑅 𝜀 = 	 𝑟$%	𝐷 𝜀1 + (𝑟$% R)	 	𝑊 𝜀𝐿 𝜀 	𝑟$% +		 𝐿 𝜀𝑊 𝜀 	 1𝑟$% ,																									(16) 
where 𝑅 𝜀  has been obtained from equations (11) and (15). Substituting the inverse function 𝜀(𝑅) 
into 𝑊 𝜀  then gives the explicit relation 𝑊(𝑅). Tradeoff functions of this form are shown in Fig. 
2 and Fig. S4.  
Maximum-growth and critical resistance trajectories. For a given resistance mechanism, the 
fitness model also predicts the maximum growth rate of mutants as a function of the drug level,  𝐺\ 𝑑 = max~ 𝐺 𝑑, 𝜀 . (17) 
Hence the maximum-growth rate is obtained as the envelope of the family of growth curves of 
mutants with a common resistance mechanism, parameterized by the trait amplitude 𝜀. To evaluate 
the condition (17), we use again the inverse function 𝑑 𝑑/0$% = 	Δ(𝐺, 𝜀), where Δ 𝐺, 𝜀 = 	𝐷 𝜀 	𝛿 𝐺𝑊(𝜀) , 𝑟𝑊(𝜀)𝐿(𝜀)  
is given by equations (10), (14), and (15). This determines the maximum growth trajectory in 
parametric form. The growth rate 𝐺\ 𝜀  is obtained from the condition 𝜕~Δ 𝐺, 𝜀 = 0,	which 
amounts to finding the largest positive solution of the cubic equation  2𝑟$% R𝐿𝑊𝐷𝜕~ log 𝐿𝑊𝐷 𝐺\{ + 2𝑟$% R𝐿𝑊R𝐷𝜕~ log 𝐷𝐿 𝐺\R − 	𝐿{𝑊𝐷𝜕~ log 𝐷𝐿𝑊 𝐺\	 + 	𝐿{𝑊R𝐷𝜕~ log 𝐷𝐿 	= 0. 
 (18) 
The corresponding drug level is given by 
												𝑑\ 𝜀𝑑/0$% = Δ 𝐺\ 𝜀 , 𝜀 = 	𝐷 𝜀 𝑊 𝜀 − 𝐺\ 𝜀 𝐿R 𝜀 − 2𝑟$%𝐺\ 𝜀 R1 +	 𝑟$% R 𝐺\ 𝜀 𝐿 𝜀 𝑊(𝜀) .																								(19) 
Maximum-growth trajectories are shown in Fig. 3a, 4a, and S4. In a similar way, the critical 
resistance trajectory 𝑅\ 𝑑 , which gives the resistance level of maximum growth-mutants as a 
function of the drug-level, can be evaluated in parametric form, using the relations (16) and (19). 
Critical resistance trajectories are shown in Fig. 3bc. We emphasize that these maximum growth 
trajectories emerge for any evolutionary mechanism with a continuous effect parameter acting 
upon a metabolic growth law, as given by equations (10), (14), and (15).  
Variation of nutrient conditions. Fitness depends not only on drug level but also on nutrient 
conditions. Specifically, the nutrient level sets the wild type nutritional capacity relative to a 
reference medium,  
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𝜈 = 	 𝜅G	$%𝜅G	i = 𝑞$%𝑞i 	 , (20) 
which, in turn, determines the relation of drug-free growth rates,  𝜆0$%𝜆0i = 𝜈(𝑞i + 1)𝜈𝑞i + 1 	. (21) 
The fitness model (14) then predicts how mutant growth rates jointly depend on drug and nutrient 
level,  𝜆𝜆0i = 𝜈(𝑞i + 1)𝜈𝑞i + 1 	𝐺 𝜀, 𝑑;	𝜈𝑞i, 𝜈(𝑞i + 1)𝜈𝑞i + 1 	𝑟i . (22) 
This transformation uses the assumption that the drug response rate 𝜆∗	is an intrinsic parameter 
independent of the environment. In Fig. 4d, we use equation (22) to predict growth curves of 
membrane permeability mutants in glycerol minimum medium, using rich medium as a reference 
(see also Data Analysis below). 
Specific resistance mechanisms. In the following, we specify the fitness model of equations (14), 
(15) for the quantitative resistance traits discussed in the main text.  
(a) Membrane permeability. The minimal model of membrane-based resistance evolution is 
defined by a coupled reduction of drug and nutrient uptake with a permeability parameter 𝜀 <1, as given by equation (2) of the main text. Using equation (9), we obtain a fitness model with 
transformation functions 𝐷 𝜀 = 1𝜀 	, 𝐿 𝜀 = 1, 𝑊 𝜀 = 𝜀 𝑞$% + 1𝜀𝑞$% + 1 	. (23) 
The resulting maximum-growth trajectories, as given by equations (20) and (21), take the 
simple form  𝐺\ 𝜀 = 	 𝜀	(𝑞$% + 1)𝜀𝑞$% + 2 ,						𝑑\ 𝜀𝑑/0$% = 𝑞$% 1 − 𝐺\ 𝜀 + 1 R( 2𝑟$% R𝐺\R 𝜀 + 1)4	(1 + 𝑟$% R) 𝑞$% + 1 	𝐺\R(𝜀) , (24) 
which is used in the main text. Results from this model are plotted in Fig. 2, 3, and 4. The 
growth curves in minimal glycerol are obtained by using the transformation (22) with 
parameter 𝜈 = 	𝑞$%/	𝑞i = 0.18	/	5.9 (Fig. 4d). We note that the membrane permeability 
model applies to any molecular uptake mechanism that affects drug and nutrients 
proportionally, as given by equation (2). In contrast, the Cpr stress response system, which is 
observed in minimal glycerol, affects drug and nutrients via different pathways. Hence, the 
proportionality constraint, equation (2), no longer applies, which is consistent with an observed 
growth curve 𝐺 𝑑  outcompeting the prediction of equation (24).  
We also consider an extended membrane model with proportional reduction of the drug uptake 
and release rates,  𝜀 = 𝛾9:		𝛾9:$% = 𝛾<=%	𝛾<=%$% = 𝜅G	𝜅G$% < 1	, (25) 
which has the transformation functions  
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𝐷 𝜀 = 1𝜀		 , 𝐿 𝜀 = 𝜀	, 𝑊 𝜀 = 𝜀 𝑞$% + 1𝜀𝑞$% + 1 	. (26) 
Under irreversible drug metabolism, which applies our regime of membrane-based resistance 
evolution (Fig. 4), the extended membrane model produces similar growth curves as the 
minimal model (Fig. S4a), as expected from the drug action model of ref. (19). For comparison, 
Fig. S4b shows growth curves of the minimal membrane model under reversible drug 
metabolism, which applies, for example, to the aminoglycosides tetracycline (43) and 
chloramphenicol (44).   
(b) Efflux pumps. Our minimal model describes an increase in the drug efflux rate 𝛾<=%	by a 
constitutive over-expression of efflux pumps at a proteome fraction 𝜑,  𝜀 = 𝛾<=%𝛾<=%$% = 𝜑𝜑$% > 1. (27) 
This over-expression reduces the maximum growth rate (17, 45) and causes a fitness cost 𝐶/𝐶$% = 𝛥𝜑H,LMN/𝛥𝜑H,LMN$% = 1	– 𝜀 − 1 𝑐	;	the cost parameter 𝑐	 = (1/𝐶)(𝜕𝐶/𝜕𝜀) 	=𝜑$%/𝛥𝜑H,LMN measures the fraction of the growth-related proteome invested for the expression 
of efflux pumps and other constitutive cost factors, such as energy consumption.  
Together with equation (9), we obtain the transformation functions  𝐷 𝜀 = 𝜀	𝑊 𝜀 	, 𝐿 𝜀 = 	 𝜀, 𝑊 𝜀 = 1	– (𝜀 − 1)𝑐		. (28) 
The resulting maximum-growth trajectories 𝐺\,(𝑑) are given in parametric form by the 
relations  𝐺\, 𝜀 ,																𝑑\, 𝜀𝑑/0$% = 1 + 𝑐	 − 𝐺\ + 4𝑐	 𝑟$%𝐺\ R	4( 𝑟$% R + 1)𝑐	𝐺\ , (29) 
where 𝐺\, is the positive solution of  2𝑟$% R𝑐𝐺\,R +	𝐺\,	 + 𝑐 2𝜀 − 1 − 1 = 0. 
In the intermediate drug regime (𝑑/𝑑/0$% < 5) and under irreversible drug metabolism (𝑟$% ≫1), these trajectories remain below those of membrane mutations. Hence, in this regime, efflux 
pumps are predicted to be a less efficient resistance mechanism than membrane permeability 
reduction in tune with the absence of efflux mutants in our Luria-Delbrück experiments. Here 
we use an order-of-magnitude estimate of the cost parameter, 𝑐	~10[R, which can be inferred 
from measurements of the fitness cost of efflux pumps (3, 46, 47). The minimal model makes 
a conservative assumption: the fitness cost of efflux pumps arises primarily by changes in 
proteome resource allocation due to their constitutive over-expression. Other cost factors, 
including load-dependent energy consumption of pumps and loss of nutrients by efflux, can 
shift the fitness balance of efflux pumps.  
Evolutionary switches between resistance mechanisms. As discussed above, the wild type 
partially offsets the action of ribosome-targeting drugs by upregulation of its ribosome content 
according to equation (12). Given the evolutionary cost 𝑊 of resistance mutations, the regulated 
wild-type is always the maximum-fitness strain at sufficiently low drug levels. Our fitness model 
predicts a switch from regulation to membrane-based resistance evolution. The onset of evolution 
occurs at a drug level 𝑑iL(𝑞$%, 𝑟$%) determined by the condition 
	 18	
𝑔 𝑑iL, 𝑟$% = 𝐺\ 𝑑iL, 𝑞$%, 𝑟$% , (30) 
which compares the wild-type growth curve and the maximum-growth trajectory of membrane 
evolution, equations (8) and (17). The resulting crossover point is given in parametric form,  					𝐺iL 𝑞$% = 	𝐺\ 𝜀 = 1, 𝑞$% = 	𝑞$% + 1𝑞$% + 2 , 𝑑iL 𝑞$%, 𝑟$% = 𝑑\ 𝜀 = 1, 𝑞$%, 𝑟$% , (31) 
which can be evaluated from equation (18) (Fig. 4a). The predicted crossover for streptomycin in 
rich LB is at 𝑑iL = 0.43 𝑑/0$%, in qualitative agreement with previously observed onset of adaptive 
resistance evolution at sub-MIC levels (9). More generally, our model can be used to compare 
arbitrary resistance mechanisms. Given two mechanisms A, B with maximum-growth curves 𝐺\, 
and 𝐺\,, a selective switch between these mechanisms is predicted at a crossover point 𝑑 given 
by 𝐺\, 𝑑, 𝑞$%, 𝑟$% = 	𝐺\, 𝑑, 𝑞$%, 𝑟$% . 
 
3. Data analysis 
Inference of model-based growth curves. For the wild type and each membrane mutant, we 
independently fit the experimental growth data to growth curves of the form  𝜆 𝑑 	= 𝜆0𝑔 𝑑𝑑∗ , 𝜆0𝜆∗	 	 , (32) 
where 𝜆0 is the drug-free growth rate and 𝑔(𝛿, 𝑟) is a drug response curve of the form (10), as 
given by the metabolic model of Greulich et al. (19). The fitted growth curves are plotted in Fig. 
S2 together with the growth measurements. Each fit involves three independent parameters: the 
rate 𝜆0	and the drug response parameters 𝑑∗, 𝜆∗. We note that in the regime of low expected growth 
(𝜆/𝜆0$% ≲ 0.1), the correspondence between data and model is confounded by two effects: mutants 
in this regime are unlikely to reach the detection threshold in Luria-Delbrück assays, and new 
metabolic effects an invalidate quantitative model predictions (49). However, the fit parameters 
are determined predominantly by data points outside this regime, leading to a robust inference 
procedure.  
Model growth curves are gauged by an error score 𝑆 = 	 𝐸(𝜆 , 𝜆), where the index 𝑖 runs over 
all measurements of a given growth curve, 𝜆 is the measured growth rate, and 𝜆 is the 
corresponding model rate. We use an error function 𝐸 𝜆, 𝜆 = (𝜆 − 𝜆)R/𝜎R for 𝜆 > 𝜆L9: and 𝐸(𝜆, 𝜆) = (max	(𝜆, 𝜆L9:) − 𝜆L9:)R/𝜎R for 𝜆 ≤ 𝜆L9:, taking into account measurement errors of 
order 𝜆L9: = 0.03	𝜆0$% preventing detection of small growth rates. We use an expected square error 
of the form 𝜎R = max Var 𝜆 , 𝜆L9:R ,	where Var 𝜆  is the recorded variance of replicate 
measurements. Numerical minimization uses simplex search by the Nelder-Mead algorithm (48) 
(we check convergence with varying initial conditions). To obtain these distributions we perform 
1000 fits to synthetic growth inhibition curves for each mutant and extract the corresponding 
optimal parameters. Synthetic growth curves are sampled from distributions defined by the 
experimental data points: Above the threshold 𝐺L9:, we use Gaussian distributions with mean and 
standard deviation given by the measurements in biological replicates. If no growth is reported, 
we sample from a uniform distribution in the interval [0, 𝐺L9:]. This posterior distribution 
determines the posterior average values, which turn out to be very close to the corresponding 
maximum-likelihood values, and the 90% confidence intervals reported in Table S2. Raw 
experimental data is given in Tables S3 and S4.  
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In rich medium, we infer the wild type parameters 𝜆0$% =	2.02 (1.98, 2.10)/hr, 𝑑∗$% =3.13	(2.98, 3.23)	mg/L, and 𝜆∗$% = 	0.37	(0.35, 0.40)/	hr (posterior average value, 90% 
confidence interval), resulting in the dimensionless drug response parameter 𝑟$% =	5.42	(5.21, 5.60). The inferred parameters 𝜆0, 𝑑∗, 𝜆∗	for all membrane mutants are reported in 
Table S2 in units of the corresponding wild type parameters; we define the scaled drug-free growth 
rate 𝑊 = 𝜆0/𝜆0$%. The fitted growth curves also produce inferred values of the membrane 
permeability, 𝜀 = 𝛾9:/𝛾9:$% = 	 λ∗𝑑∗$%	/(λ∗$%𝑑∗), and the drug release rate, 𝛾<=%/𝛾<=%$% = 𝜆∗/λ∗$% R, 
for all mutants; see equation (9) (Table S2).  
The wild type parameter 𝑞$% = 	𝜅G$%/𝜅H$%	 in rich medium is obtained independently from the 
spectrum of drug-free mutant growth rates, 𝑊(𝜀), as given by equation (3). The empirical 
spectrum is of the Michaelis-Menten form, equation (1), if the permeability parameter is re-
interpreted as the nutritional capacity relative to the wild type, 𝜀 = 	𝜅G/𝜅G$%. This identification is 
consistent under the assumption that membrane mutations have no effect on translation, i.e., 𝜅H =	𝜅H$% for all mutants. The Michaelis-Menten fits produce the inferred parameter 𝑞$% =5.9	(5.5, 6.3); the maximum-likelihood fit is shown in Fig. 2. While 𝜅G$% and 𝜅H$% can be inferred 
from solely from wild-type (RNA and proteomics) data (17), the evolutionary cost pattern 𝑊 𝜀 	provides an alternative, simple way of extracting the ratio 𝑞$% that does not require 
expression data.  
The experiments in minimal glycerol medium operate at significantly reduced growth rates 
(𝜆 ≤ 𝜆0$% = 0.39/hr). In the low-growth regime (𝜆 ≲ 0.2/hr), we observe a different growth 
pattern with an extended lag phase, and metabolic differences in ribosome function and utilization 
have been reported at low growth rates (49). Here we obtain a model-based growth curve for the 
wild-type by equation (22), constraining 𝜆∗$% to its value in rich medium and allowing an 
independent fit of 𝑑∗$%. This parameter can change, in particular, with metabolic shifts affecting 
the growth-related proteome fraction, 𝐶; see equation (7). Fitting this model to the points of 
observed positive growth, we obtain 𝑑∗$% = 2.0	mg/L and 𝜆0$% = 0.39/hr, corresponding to 𝑞$% =0.2 and 𝑟$% = 1.05; the resulting dosage response curve is shown in Fig. 4b and Fig. S2b. In the 
low-growth regime, model-based growth curves should be regarded as upper bounds to observed 
growth rates.  
Fit quality and comparison of membrane models. Fitting the metabolic drug response model 
(19) to our wild type and membrane mutant growth curves produces a total error score 𝑆 = 130 
for a total of 150 independent measurements in 24 strains. The score per measurement is of order 
1, which implies the metabolic model reproduces the empirical data within measurement errors 
(Fig. S2). We can also compare the full membrane model with an alternative model with the global 
constraint 𝜆∗ = 	 𝜆∗$%, which amounts to fixing the drug release rate, 𝛾<=%, of all mutants to the wild 
type value. The constrained model produces a fit of comparable quality, which has a total error 
score 𝑆 = 154 for a total of 130 independent measurements in 21 strains (excluding the outliers 
in Fig. S3). We conclude that variation of 𝛾<=% across mutants is negligible for most growth curves 
of our membrane mutants (see also Fig. S3). This asymptotic independence is expected in the so-
called irreversible drug response regime (𝑟 ≫ 1) described in ref. (19).  
Validation of the fitness model. The empirical growth curve of a given membrane mutant has 
two characteristic drug levels that are important for testing the membrane fitness model.  
(i) The half-inhibitory concentration, 𝑑/0, has the simple form 𝑑/0 = (𝑑∗/2)(𝜆0/𝜆∗ + 𝜆∗/𝜆0) in 
terms of the basic growth parameters 𝜆0, 𝑑∗, 𝜆∗ obtained from our fitting procedure; see 
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equation (11). The resulting resistance values 𝑅 = 	𝑑/0/𝑑/0$% are reported in Table S2 for all 
membrane mutants. The empirical parameter 𝑅 depends solely on the drug response curve 𝑔 
of a given mutant; a priori, the drug-free growth 𝑊 =	𝜆0/𝜆0$% can vary independently across 
the set of membrane mutants. Our fitness model establishes a unique relation 𝑊(𝑅), which is 
given in parametric form by equation (3). This relation is found to be in quantitative agreement 
with the empirical pattern (Fig. 2c).  
(ii) The critical drug concentration, 𝑑\, is the point where a given mutant is predicted to confer 
maximum fitness against all other membrane mutants. This point is defined by equation (24) 
solely in terms of the mutant permeability parameter, 𝜀 = 𝛾9:/𝛾9:$%, and the wild type 
parameters 𝑞$%, 𝑟$%. Our fitness model predicts the growth rate of that mutant at the critical 
drug concentration, 𝐺\ 𝜀 ,	by equation (4). This relation is validated in Fig. 3a. Notably, the 
critical growth rate becomes independent of the parameter 𝑟$%. 
Inference of mutation rates. Our Luria-Delbrück assays in rich agar record a drug-dependent 
establishment rate of membrane mutants, 𝑢c 𝑑 , which strongly decreases with increasing 𝑑 in 
the intermediate-dosage regime (𝑑/𝑑/0$% > 2) (Fig. 4a, Table S5). We estimate an effect-dependent 
spectrum of membrane mutations, using the heuristic form 𝑈c 𝑅 	~	𝑢0/(1 + exp	[𝑎 𝑅 − 𝑅0 ] 
and the relation 𝑈c 𝑑 = 	 𝑈 𝑅 	𝜃 𝐺 𝑑, 𝜀(𝑅) −	𝐺%i 	𝑑𝑅, where 𝐺L9: ≈ 	0.1 is the minimum 
relative growth rate giving rise to detectable colonies after an overnight culture and 𝐺 𝑑, 𝜀 	is the 
growth rate given by our fitness model. The fitted mutational spectrum has parameters 𝑢0 =3.6×10[d, 	𝑎 = 3.4, 𝑅0 = 2.7 (Fig. S5a).  
Target mutations appear in rich agar in the dosage regime 𝑑/𝑑/0$% ≥ 5.5 with establishment rates 𝑈H of order 10[Q0 (Fig. 4a). We observe ten genetic variants, which have the amino acid 
substitutions P91L, P91Q, P91R, G92D, K43T, K43N, K43R, K43Q, K88R, K88E in the rpsL 
gene. Growth measurements of three prevalent variants, P91L, K43N, K43T, and the fittest variant 
K43R, reveal approximately drug-independent growth rates 𝐺 = 0.36, 0.76,0.85,0.95 for 𝑑/𝑑/0$% ≥ 5.5. Establishment rates for individual variants are estimated from observed frequencies 
of mutant colonies (Fig. S5a). In minimal glycerol, target mutations have establishment rates of 
order 10[Q0 (Fig. 4c). We observe 4 genetic variants with substitutions K88R, K43T, K43N, and 
K43R in the rpsL gene, all of which have approximately drug-independent growth rates 𝐺 > 0.9 
for 𝑑/𝑑/0$% ≥ 1.9. Stress response mutations in the gene cpxA are observed only in minimal 
glycerol at 𝑑/𝑑/0$% = 0.9	with an establishment rate 𝑈\op~10[q (Fig. 4c).  
These mutational spectra are used as input to determine the growth rate spectrum at a given drug 
level, 𝑈(𝐺; 𝑑), which governs short-term evolution experiments (Fig. S5b), as well as the 
normalized distributions 𝑃]^(𝑅; 𝑑) and 𝑃]^(𝐺; 𝑑) relevant for Luria-Delbrück assays (Fig. S5cd).  
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Supplementary Figures and Tables  
 
 
 
 
Fig. S1: Genomics and mechanisms of resistance evolution. (a) Genomic distribution of resistance 
mutations found in the Luria-Delbrück experiments of this study. Bars indicate the genomic coordinates of 
affected genes, multiple distinct mutations in a given gene are marked by numbers. Functional classes of 
these mutations include membrane active transport (cyan, 17 distinct genome mutations in 23 clones grown 
in rich medium), drug target modifications (orange, 10 distinct amino acid changes in the rpsL gene in rich 
medium, 4 in minimal glycerol medium, and Cpx stress response (green, 4 distinct amino acid changes in 
the gene cpxA in minimal glycerol medium). These functional classes account for 94% of the resistance 
mutants found in this study; all mutations are listed in Tables S3 and S4. (b) Schematic representation of 
key pathways involved in active membrane transport (mutated genes in brackets and marked in cyan): 
ubiquinone biosynthesis (ubiA, ubiI, ubiH, ubiK), ATP biosynthesis (atpG), heme biosynthesis (hemC), 
methylerythritol phosphate pathway (dxs, ispH), NADH-cytochrome oxidase electron transfer (ndh, cydA, 
cydB); see Table S1.  
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Fig. S2: Drug-dependent growth curves. (a) Rich liquid medium. Data points show growth rates of the 
wild type and of membrane mutants at different drug levels 𝑑 (measured in units of the half-inhibitory 
concentration of the wild type, 𝑑/0$% = 8.7mg/L). Bars indicate rms. experimental uncertainties, colors mark 
the drug level of the Luria-Delbrück assay used to elicit each mutant, 𝑑]^/𝑑/0$% = 0.9, 1.9, 3.6 (violet, pink, 
red). Empirical growth curves, 𝜆(𝑑) 𝜆0$% = 𝐺(𝑑;𝑊, 𝑑/0∗ , 𝜆0∗ ) (lines) involve three independent fit 
parameters for each mutant: the drug-free growth rate, 𝑊 = 𝜆0 𝜆0$%, and the drug response parameters (19) 𝑑/0∗ , 𝜆0∗ ; see equation (9). These fits also produce estimates of the membrane transport rates, 𝛾9: and 𝛾<=%, 
and of the characteristic drug levels 𝑑\ and 𝑑/0. For each mutant, the critical point (𝑑\, 𝐺(𝑑\)) (square) 
gives the empirical growth rate at the predicted critical drug concentration; this point is used in Fig. 3a. 
Inferred growth and resistance parameters for all membrane mutants are listed in Table S2, raw data are 
reported in Table S3.  (b) Minimal glycerol liquid medium. Data points show growth rates of the wild type 
and of cpx stress response mutants elicited at 𝑑]^/𝑑/0i = 0.9. All drug levels are measured in units of 𝑑/0i = 8.7mg/L. The fit procedure is detailed in Methods.  
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Fig. S3: Membrane model of drug resistance. We compare (a) uptake rate, 𝜀	 = 𝛾9:/𝛾9:$%, (b) drug-free 
growth rate, 𝑊	 = 𝜆0/𝜆0$%, and (c) resistance, 𝑅	 = 𝑑/0/𝑑/0$%, of membrane mutants obtained from our full 
inference procedure with the corresponding values from a constrained model with fixed parameter 𝜆∗ =	2(𝛾<=%	𝜅H0𝐾)Q/R = 	 𝜆∗$%. Drug-free growth and resistance show insignificant changes, the uptake rate 
changes significantly in only three mutants.  Hence, variation of the parameter 𝛾<=% does not affect the 
inference of the membrane model (equation (2)), of the evolutionary tradeoff 𝑊(𝑅) (Fig. 2), and of the 
empirical data reported in Fig. 3.  
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Fig. S4: Comparison of evolutionary resistance mechanisms. Evolutionary tradeoff curves, 𝑊 𝑅 , and 
maximum-growth trajectories, 𝐺\ 𝑑 , are shown for the following models: (a) Minimal membrane 
permeability evolution (reduction of uptake rates, 𝛾9:/𝛾9:$% = 𝜅G/𝜅G$%, at constant release rate, 𝛾<=%/𝛾<=%$% =	1, as in main text) and an extended model (reduction of uptake and release rates, 𝛾9:/𝛾9:$% = 𝜅G/𝜅G$% = 𝛾<=%/𝛾<=%$% ) are compared in the growth regime of irreversible drug metabolism (19) (	𝑟$% ≫ 1). In this 
regime, release rates have a negligible influence on growth and resistance, supporting use of the minimal 
model. Model parameters: 𝑞$% = 	5.9, 	𝑟$% = 	5.4	as in main text. (b, c) Evolution of drug efflux pumps 
(increase of drug release rate by overexpression of efflux genes, 𝛾<=%/𝛾<=%$% = 𝜑/𝜑$% ) and minimal 
membrane evolution are compared in regimes of irreversible (𝑟$% ≫ 1) and reversible growth (𝑟$% ≲ 1). 
Efflux pumps are predicted to be relatively inefficient specifically under irreversible growth. Model 
parameters: efflux cost parameter, 𝑐 = 5×10[{, 1×10[R, 1.5×10[R	(top to bottom),	𝑞i = 	5.9, 	𝑟i =5.4	(irreversible regime, as in main text), 𝑞$% = 	5.9, 	𝑟$% = 0.9	(reversible regime). The reversible regime 
can be attained by applying a drug with reduced ribosome binding affinity (i.e., with increased equilibrium 
constant 𝐾) for a given wild-type (i.e., at constant 𝜆0$%). This results in increased drug response parameters 𝜆∗$% and 𝑑∗$% compared to the reference drug; see equation (9).  
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Fig. S5: Resistance mutation spectra in evolution and selection assays. (a) Spectrum of resistance 
mutation rates, 𝑈(𝑅), inferred from Luria-Delbrück assays (cyan: membrane mutations; orange: rpsL 
mutations). Dashed horizontal lines indicate threshold population sizes; resistance effects above a given 
line are likely to be represented in a population of given size 𝑁. (b) Resulting spectrum of mutant growth 
rates in rich LB at different drug levels, 𝑈(𝐺; 𝑑), aggregated from the mutation rate spectrum 𝑈(𝑅), the 
fitness model for membrane mutations, and the measured growth rates of target mutations. Arrows mark 
the maximum growth rate attainable by short-term evolution at a given population size. The low-growth 
component corresponds to unobservable low-resistance mutants. (c, d) Resulting normalized distributions 
of resistance effects and growth rates of mutant colonies in Luria-Delbrück assays, 𝑃]^(𝑅; 𝑑) and 𝑃]^(𝐺; 𝑑), at different drug levels. Filled squares indicate growth rate segments with probability > 0.04, 
dots mark observed mutants (as in Fig. 4a).  
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Table S1: Membrane-associated resistance mutations: genes, pathways, and functions.  See reference 
(52) for a description of genes, encoded proteins, and their physiological role. 
  
Gene Protein 
location 
Pathway Pathway function  Likely functional effect 
of mutation 
ispH  Cytoplasm Methylerythritol- 
phosphate pathway  
Precursor for 
ubiquinol/ubiquinone 
biosynthesis pathway 
Reduced ubiquinol /  
ubiquinone levels  
dxs  Cytoplasm Methylerythritol- 
phosphate pathway 
Precursor for 
ubiquinol/ubiquinone 
biosynthesis pathway 
Reduced ubiquinol /  
ubiquinone levels  
cydA-
mngB  
Inner 
membrane 
NADH – cytochrome 
oxidase electron transfer 
Cytochrome bd-I ubiquinol 
oxidase subunit 1 
Reduced cydA 
expression  
cydB  Inner 
membrane 
NADH – cytochrome 
oxidase electron transfer 
Cytochrome bd-I ubiquinol 
oxidase subunit 2 
Reduced ubiquinone 
levels 
ndh Inner 
membrane 
NADH – cytochrome 
oxidase electron transfer 
Quinone oxidoreductase 
enzyme 
Impaired cytochrome 
oxidase   
ubiA Inner 
membrane 
Ubiquinone biosynthesis 
pathway 
Ubiquinone biosynthesis Reduced ubiquinol /  
ubiquinone levels 
ubiI  Cytoplasm Ubiquinone biosynthesis 
pathway 
Ubiquinone biosynthesis Reduced ubiquinol /  
ubiquinone levels 
ubiH  Cytoplasm Ubiquinone biosynthesis 
pathway 
Ubiquinone biosynthesis Reduced ubiquinol /  
ubiquinone levels 
ubiK  Cytoplasm / 
Inner 
membrane 
Ubiquinone biosynthesis 
pathway 
Ubiquinone biosynthesis Reduced ubiquinol /  
ubiquinone levels 
atpG  Inner 
membrane 
ATP biosynthesis 
pathway  
ATP synthase subunit 
involved in ATP synthesis 
Impaired ATP synthesis  
hemC  Cytoplasm Heme biosynthesis 
pathway 
Synthesis of cofactors for 
ubiquinol oxidases (cydA, 
cydB) 
Reduced ubiquinol /  
ubiquinone levels 
arcB  Cytoplasm /  
Inner 
membrane 
NADH – cytochrome 
oxidase electron transfer, 
other pathways 
Positive regulator of cydA 
expression (50, 51) 
Reduced cydA 
expression 
selB  Cytoplasm Electron transfer Translation factor, insertion 
of seleno-cysteine into 
membrane peptides 
Modification of 
membrane-bound 
dehydrogenases  
ratA Cytoplasm  Ribosome associated toxin /  
ubiquinone-binding protein 
Reduced ubiquinone 
levels  
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Mutant 
number 
  ¡				¢£ 	 𝑊 = 𝜆0𝜆0$% 𝑑∗𝑑∗$%	 𝜆∗		𝜆∗$%	 
1 0.9 0.87 (0.83, 0.91) 4.31 (3.10, 4.86) 1.79 (1.23, 2.14) 
2 0.9 0.82 (0.78, 0.86) 3.42 (3.31, 3.42) 1.68 (1.59, 1.74) 
3 0.9 0.93 (0.89, 0.96) 2.70 (2.56, 2.88) 1.38 (1.30, 1.42) 
4 0.9 0.63 (0.61, 0.66) 0.74 (0.71, 0.80) 0.14 (0.14, 0.16) 
5 0.9 0.88 (0.84, 0.92) 1.52 (1.31, 1.57) 1.47 (1.23, 1.51) 
6 0.9 1.00 (0.96, 1.04) 0.43 (0.41, 0.44) 0.29 (0.28, 0.31) 
7 0.9 0.22 (0.20, 0.25) 2.78 (2.49, 3.02) 0.34 (0.30, 0.45) 
8 1.8 0.72 (0.68, 0.77) 3.15 (2.85, 3.20) 0.99 (0.88, 1.02) 
9 1.8 0.87 (0.83, 0.92) 3.73 (3.30, 3.93) 2.62 (2.10, 3.10) 
10 1.8 0.53 (0.50, 0.55) 0.06 (0.06, 0.07) 0.01 (0.01, 0.01) 
11 1.8 0.78 (0.76, 0.82) 2.97 (2.92, 3.06) 1.00 (1.00, 1.05) 
12 1.8 0.63 (0.60, 0.67) 3.40 (3.13, 3.46) 0.70 (0.63, 0.72) 
13 1.8 0.73 (0.68, 0.76) 3.36 (3.29, 3.65) 0.87 (0.85, 0.92) 
14 1.8 0.92 (0.87, 0.97) 4.19 (3.73, 4.33) 1.84 (1.74, 2.37) 
15 1.8 0.88 (0.84, 0.93) 2.12 (1.39, 2.19) 1.39 (1.02, 1.48) 
16 3.7 0.68 (0.63, 0.74) 6.20 (5.13, 6.86) 2.06 (1.57, 2.62) 
17 3.7 0.49 (0.47, 0.53) 6.84 (6.35, 7.14) 1.02 (0.92, 1.09) 
18 3.7 0.60 (0.56, 0.64) 6.84 (6.23, 7.83) 0.98 (0.84, 1.04) 
19 3.7 0.68 (0.66, 0.71) 4.00 (3.80, 4.11) 0.72 (0.69, 0.76) 
20 3.7 0.51 (0.48, 0.54) 6.83 (6.42, 7.08) 1.04 (0.96, 1.12) 
21 3.7 0.58 (0.55, 0.61) 4.97 (4.53, 5.01) 0.69 (0.62, 0.72) 
22 3.7 0.58 (0.54, 0.61) 4.98 (4.59, 5.18) 0.78 (0.70, 0.80) 
23 3.7 0.57 (0.54, 0.61) 6.20 (5.56, 6.58) 0.78 (0.66, 0.84) 
 
 
 
Mutant 
number 
𝜀	 = 𝛾9:𝛾9:$% 𝛾<=%𝛾<=%$%  𝑅	 = 𝑑/0𝑑/0$% 𝑑¤𝑑/0$% 
1 0.43 (0.38, 0.49) 3.01 (1.58, 4.80) 2.25 (2.09, 2.38) 1.35 (1.14, 1.53) 
2 0.51 (0.47, 0.56) 3.06 (2.55, 3.30) 1.77 (1.67, 1.87) 1.07 (0.97, 1.19) 
3 0.52 (0.49, 0.57) 1.96 (1.71, 2.21) 1.83 (1.73, 1.91) 1.04 (0.94, 1.13) 
4 0.20 (0.19, 0.22) 0.02 (0.02, 0.03) 3.00 (2.83, 3.13) 2.71 (2.52, 2.88) 
5 0.99 (0.90, 1.08) 1.88 (1.52, 2.39) 0.94 (0.88, 0.99) 0.45 (0.39, 0.51) 
6 0.70 (0.66, 0.76) 0.09 (0.08, 0.10) 1.38 (1.31, 1.44) 0.71 (0.64, 0.78) 
7 0.13 (0.11, 0.17) 0.13 (0.09, 0.21) 1.76 (1.53, 1.90) 3.71 (3.15, 4.14) 
8 0.32 (0.30, 0.36) 0.99 (0.79, 1.13) 2.29 (2.16, 2.40) 1.79 (1.62, 1.95) 
9 0.72 (0.59, 0.93) 7.12 (4.56, 10.20) 1.52 (1.32, 1.70) 0.70 (0.47, 0.91) 
10 0.15 (0.13, 0.15) 0.00 (0.00, 0.00) 3.66 (3.46, 3.85) 3.62 (3.37, 3.85) 
11 0.35 (0.33, 0.38) 1.07 (0.98, 1.18) 2.29 (2.17, 2.40) 1.64 (1.52, 1.76) 
12 0.21 (0.20, 0.24) 0.49 (0.41, 0.57) 2.97 (2.79, 3.12) 2.61 (2.40, 2.79) 
13 0.27 (0.24, 0.29) 0.83 (0.72, 0.92) 2.75 (2.59, 2.90) 2.16 (1.98, 2.33) 
14 0.45 (0.42, 0.62) 4.14 (3.07, 5.81) 2.11 (1.78, 2.33) 1.14 (0.85, 1.34) 
15 0.67 (0.62, 0.95) 1.76 (1.09, 2.35) 1.27 (0.99, 1.43) 0.69 (0.47, 0.84) 
16 0.34 (0.27, 0.48) 4.51 (2.54, 7.12) 2.52 (2.11, 2.85) 1.70 (1.16, 2.13) 
17 0.15 (0.14, 0.17) 1.08 (0.87, 1.27) 3.56 (3.34, 3.74) 3.35 (3.07, 3.59) 
18 0.15 (0.11, 0.17) 0.95 (0.72, 1.15) 4.43 (3.84, 5.14) 3.54 (3.07, 4.08) 
19 0.19 (0.17, 0.21) 0.55 (0.48, 0.62) 3.64 (3.40, 3.83) 2.88 (2.67, 3.07) 
20 0.16 (0.14, 0.18) 1.13 (0.93, 1.33) 3.55 (3.33, 3.74) 3.29 (3.02, 3.53) 
21 0.14 (0.13, 0.16) 0.48 (0.40, 0.56) 4.02 (3.74, 4.28) 3.48 (3.21, 3.74) 
22 0.16 (0.14, 0.18) 0.58 (0.49, 0.68) 3.70 (3.49, 3.88) 3.28 (3.04, 3.52) 
23 0.13 (0.11, 0.16) 0.60 (0.46, 0.75) 4.58 (3.99, 5.35) 3.78 (3.31, 4.32) 
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Table S2: Growth and resistance data of membrane mutants. (1) Mutant number. (2) Drug level of 
Luria-Delbrück assay, 𝑑]^/𝑑/0$%. (3,4,5) Posterior average parameters of the membrane evolution model: 
resistance cost, 𝑊	 = 𝜆0/𝜆0$%; drug response parameters, 𝑑∗	 /𝑑∗$%, 𝜆∗		/𝜆∗$%. (6,7) Membrane transport rates: 
uptake rate 𝜀	 = 𝛾9:/𝛾9:$%; release rate, 𝛾<=%/𝛾<=%$% . (8) Resistance, 𝑅	 = 𝑑/0/𝑑/0$%.  (9) Critical drug level, 𝑑¤/𝑑/0$%. All concentrations and rates are reported in units of the wild type parameters 𝑑/0$% =	8.66	mg/L, 𝜆0$% = 2.02, 𝑑/0∗$% = 3.13	mg/L, 𝜆0$% = 2/h, 	𝜆∗$% = 0.37/h.	Measured growth rates and 
inferred growth inhibition curves are shown in Fig. S2. Inference procedures are detailed in section 3 of 
Methods.  
 
 
 
 
 
 
 
